Critical review of cancer risk associated with angiotensin receptor blocker therapy

Clicks: 322
ID: 6851
2011
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Popular

Ranked #3 of 36 articles by views in Vascular health and risk management

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Critical review of cancer risk associated with angiotensin receptor blocker therapy Grégoire Wuerzner1,3, Michel Burnier1, Bernard Waeber2,31Service of Nephrology and Hypertension Consultation, Centre Hospitalier Universitaire Vaudois, 2Division of Clinical Pathophysiology, Centre Hospitalier Universitaire Vaudois, 3Clinical Research Centre, Unil/Centre Hospitalier Universitaire Vaudois, Lausanne, SwitzerlandAbstract: The role of drugs in new cancer occurrence and cancer-related death is a major concern. Recently, a meta-analysis raised the possibility that angiotensin receptor blockers (ARBs) might have an adverse effect on patients. This generated a significant debate until the publication of two further meta-analyses, neither of which demonstrated an increased risk of new cancer occurrence or cancer-related death with the use of ARBs in patients with hypertension, heart failure, and/or nephropathy. This illustrates that the results of meta-analyses should be interpreted cautiously and critically as bias, such as selection bias, might lead to erroneous conclusions. Overall, the bulk of evidence today indicates that ARBs are not associated with increased cancer risk.Keywords: hypertension, cancer, angiotensin receptor blocker, meta-analyses
Reference Key
grgoire2011criticalvascular Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Grégoire Wuerzner;Michel Burnier;Bernard Waeber and
Journal Vascular health and risk management
Year 2011
DOI
10.2147/VHRM.S13552
URL
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.